Latest AzaSite Stories

2007-12-20 09:00:53

InSite Vision (AMEX:ISV) announced today that it has initiated pivotal Phase 3 clinical trials to evaluate AzaSite Plus™ for the treatment of blepharoconjunctivitis, a frequently-chronic inflammation of the conjunctiva and eye lids caused by infections or allergic reactions. AzaSite Plus, formulated in InSite's patented DuraSite® sustained delivery vehicle, is a topical combination antibiotic/corticosteroid product that is being developed to provide simultaneous...

2007-02-16 09:01:11

InSite Vision Incorporated (AMEX:ISV) today announced the signing of a licensing agreement with Inspire Pharmaceuticals (NASDAQ:ISPH) for the United States and Canada. The agreement provides for the commercialization by Inspire of AzaSite™ (1% azithromycin), InSite's topical anti-infective product currently under NDA review by the FDA for the treatment of bacterial conjunctivitis; commonly referred to as "pink eye". The global market...

Word of the Day
  • Wasting away as a result of abstinence from food.
The word 'abrosia' comes from a Greek roots meaning 'not' and 'eating'.